The U.S. Meals and Drug Administration (FDA) has accepted PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to assist establish sufferers with epithelial...
Minimal residual illness, or MRD, testing might have the potential to supply peace of thoughts to survivors of breast most cancers, as a survivor and...
Amongst sufferers with operable, newly recognized mind metastases, remedy with GammaTile was related to a higher than 50% discount within the danger...
Including VCN-01 (zabilugene almadenorepvec) to standard-of-care (SOC) gemcitabine plus Abraxane (nab-paclitaxel) led to improved total survival (OS), progression-free survival (PFS), and length...
Amongst sufferers with beforehand untreated, PD-L1-positive metastatic triple-negative breast most cancers (mTNBC), therapy with Trodelvy (sacituzumab govitecan) plus Keytruda (pembrolizumab) has been...
Camrelizumab together with famitinib produced superior progression-free survival (PFS) outcomes versus platinum-based chemotherapy for the frontline therapy of sufferers with recurrent or...
